XML 15 R22.htm IDEA: XBRL DOCUMENT
v3.20.1

Selected Quarterly Financial Data (Unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2019
Quarterly Financial Information Disclosure [Abstract] |
Selected Quarterly Financial Data (Unaudited) | Selected Quarterly Financial Data (Unaudited) The table below sets forth certain unaudited statements of comprehensive income (loss) data, and net income (loss) per common share data, for each quarter of 2019 and 2018: (in thousands, except per share data)
| Quarter Ended |  |  |  |  |  |
| March 31 |  | June 30 |  | September 30 |  | December 31
|  |  | (Unaudited) |  |  |  |
2019 |  |  |  |  |  |  |
Revenues (1) | $ | 9,216 |  |  | $ | 9,682 |  |  | $ | 294,448 |  |  | $ | 8,727 |
Income (loss) from operations | $ | (17,469) |  |  | $ | (18,545) |  |  | $ | 224,676 |  |  | $ | (47,217) |
Net income (loss) | $ | (21,797) |  |  | $ | (23,018) |  |  | $ | 226,086 |  |  | $ | (51,138) |
Net income (loss) per common share, basic | $ | (0.21) |  |  | $ | (0.22) |  |  | $ | 2.13 |  |  | $ | (0.48) |
Net income (loss) per common share, diluted | $ | (0.21) |  |  | $ | (0.22) |  |  | $ | 1.95 |  |  | (0.48) |
Shares used in computing net income (loss) per common share, basic | 106,054 |  |  | 106,272 |  |  | 106,272 |  |  | 106,272 |
Shares used in computing net income (loss) per common share, diluted | 106,054 |  |  | 106,272 |  |  | 116,640 |  |  | 106,272 |
2018 |  |  |  |  |  |  |
Revenues | $ | 25,374 |  |  | $ | 13,798 |  |  | $ | 6,966 |  |  | $ | 17,071 |
Loss from operations | $ | (37,713) |  |  | $ | (30,272) |  |  | $ | (22,927) |  |  | $ | (12,367) |
Net loss | $ | (41,821) |  |  | $ | (34,549) |  |  | $ | (27,396) |  |  | $ | (16,782) |
Net loss per common share, basic and diluted | $ | (0.40) |  |  | $ | (0.33) |  |  | $ | (0.26) |  |  | $ | (0.16) |
Shares used in computing net loss per common share, basic and diluted | 105,668 |  |  | 105,848 |  |  | 105,881 |  |  | 105,920 |
(1) Revenues for the three months ended September 30, 2019 include $260 million from the Sanofi Termination Agreement, as defined in Note 13. For periods presented with a net loss, the weighted average number of shares outstanding are the same for both basic and diluted net loss per common share. For these periods, shares associated with convertible debt, stock options and restricted stock units are not included in the weighted average number of shares of common stock outstanding because they are antidilutive.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -URI http://asc.fasb.org/topic&trid=2126967 + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration